← Back to Search

Other

PF-07293893 for Healthy Subjects

Phase 1
Recruiting
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Body mass index (BMI) of 16 to 32 kg/m2 and a total body weight >50 kg (110 lb)
Males 18 to 65 years of age and females of non-childbearing potential
Must not have
History of human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C
Kidney impairment as defined by an estimated glomerular filtration rate (eGFR) <75 mL/min/1.73 m²
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial is looking at how a new medicine, PF-07293893, affects muscle biomarkers in people with heart disease who struggle to exercise. They are looking for male participants between 18 to

Who is the study for?
This trial is for healthy men aged 18-65 and women who can't get pregnant, with a BMI of 16-32 and weight over 50 kg. Participants should have done less than 150 minutes of moderate or less than 75 minutes of vigorous exercise weekly in the past month.
What is being tested?
The study tests PF-07293893 against a placebo to see how it affects muscle biomarkers related to exercise capacity. Participants will take the medicine once by mouth during a four-day clinic stay, with follow-up assessments after about one month.
What are the potential side effects?
Potential side effects are not specified here but generally could include reactions at the sample collection site, changes in blood markers, or other systemic responses as observed by the research team.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My BMI is between 16 and 32, and I weigh more than 50 kg.
Select...
I am a man aged 18-65 or a woman who cannot become pregnant.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a history of HIV, hepatitis B, or hepatitis C.
Select...
My kidney function is reduced with an eGFR below 75 mL/min.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Experimental Treatment
Group I: Optional Cohort 2Experimental Treatment2 Interventions
Healthy adult participants will receive a single dose of PF-07293893 or placebo
Group II: Cohort 1Experimental Treatment2 Interventions
Healthy adult participants will receive a single dose of PF-07293893 or placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PF-07293893
2023
Completed Phase 1
~30
Placebo
1995
Completed Phase 3
~2670

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

PfizerLead Sponsor
4,625 Previous Clinical Trials
14,284,134 Total Patients Enrolled
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,518 Previous Clinical Trials
11,458,710 Total Patients Enrolled
~0 spots leftby Oct 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top